Drug intelligence / Profile preview

CDKN2A

Development stage: Preclinical
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intracerebral

Overview

CDKN2A is a gene that plays a crucial role in regulating cellular senescence. In the provided context, the gene products of CDKN2A are over-expressed in astrocytes using adeno-associated virus (AAV) serotype 9 vectors, driven by the GFAP promoter. This gene therapy approach is being investigated for its potential impact on Alzheimer's disease-like pathology and associated behavioral changes, particularly in the context of aging and the accumulation of senescent cells in the brain.

Other names: Cdkn2aCdkn-2aCdkn 2a

Targets

CDK4 (Cyclin-dependent kinase 4)MDM2 (Mouse double minute 2 homolog)CDK6 (Cyclin-dependent kinase 6)

Beyond the preview

Go deeper on CDKN2A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDKN2A.

Explore the full profile